Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche

Cancer Discovery

Volumn 5, Issue 2, 2015, Pages 168-181

  Reticker Flynn, Nathan E ^a   Bhatia, Sangeeta N ^a,b,c,d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; CD11B ANTIGEN; COLONY STIMULATING FACTOR RECEPTOR; GALECTIN 3; GALECTIN 8; GAMMA INTERFERON RECEPTOR 1; GLYCOPROTEIN; GLYCOSYLTRANSFERASE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; PEANUT AGGLUTININ; THOMSEN FRIEDENREICH ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BETA-1,3-GALACTOSYL-O-GLYCOSYL-GLYCOPROTEIN BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE 3; N ACETYLGLUCOSAMINYLTRANSFERASE; SIALYLTRANSFERASE; ST6GALNAC4 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; COPY NUMBER VARIATION; CULTURE MEDIUM; DNA HAIRPIN; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LUMINEX ASSAY; LUNG CANCER; METASTASIS; MOUSE; MURINAE; NONHUMAN; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN ISOLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; RNA TRANSLATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GALECTIN 3; GLYCOSYLATION; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; N-ACETYLGLUCOSAMINYLTRANSFERASES; NEOPLASM METASTASIS; SIALYLTRANSFERASES;

EID: 84922369348     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0760     Document Type: Article

References (54)

1. Liu F-T, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer 2005; 5: 29-41.
2. Almkvist J, Karlsson A. Galectins as inflammatory mediators. Glycoconj J 2004; 19: 575-81.
3. Rabinovich GA, Toscano MA. Turning 'sweet' on immunity: galectinglycan interactions in immune tolerance and inflammation. Nat Rev Immunol 2009; 9: 338-52.
4. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 2000; 6: 1389-93.
5. Balan V, Nangia-Makker P, Raz A. Galectins as cancer biomarkers. Cancers 2010; 2: 592-610.
6. John CM, Leffler H, Kahl-Knutsson B, Svensson I, Jarvis GA. Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res 2003; 9: 2374- 83.
7. Glinsky VV, Glinsky GV, Rittenhouse-Olson K, Huflejt ME, Glinskii OV, Deutscher SL, et al. The role of thomsen-friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res 2001; 61: 4851-7.
8. Bian CF, Zhang Y, Sun H, Li DF, Wang DC. Structural basis for distinct binding properties of the human galectins to Thomsen- Friedenreich antigen. PLoS ONE 2011; 6: e25007.
9. Yu L-G. The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression. Glycoconj J 2007; 24: 411-20.
10. Springer GF. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med (Berl) 1997; 75: 594-602.
11. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-52.
12. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009; 9: 285-93.
13. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-8.
14. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820-7.
15. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, et al. H ypoxiainduced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009; 15: 35-44.
16. Oskarsson T, Acharyya S, Zhang XHF, Vanharanta S, Tavazoie SF, Morris PG, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 2011; 17: 867-74.
17. McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008; 133: 994-1005.
18. Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr H-A, Delaloye J-F, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012; 481: 85-9.
19. Kim S, Takahashi H, Lin W-W, Descargues P, Grivennikov S, Kim Y, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009; 457: 102-6.
20. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, et al. HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13: 206-20.
21. Kim M-Y, Oskarsson T, Acharyya S, Nguyen DX, Zhang XHF, Norton L, et al. Tumor self-seeding by circulating cancer cells. Cell 2009; 139: 1315- 26.
22. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537-49.
23. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518- 24.
24. Bos PD, Zhang XHF, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459: 1005-9.
25. Qian B-Z, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475: 222-5.
26. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13: 23-35.
27. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-8.
28. Winslow MM, Dayton TL, Verhaak RGW, Kim-Kiselak C, Snyder EL, Feldser DM, et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 2011; 473: 101- 4.
29. DuPage M, Cheung AF, Mazumdar C, Winslow MM, Bronson R, Schmidt LM, et al. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 2011; 19: 72-85.
30. Reticker-Flynn NE, Malta DFB, Winslow MM, Lamar JM, Xu MJ, Underhill GH, et al. A combinatorial extracellular matrix platform identifies cell-extracellular matrix interactions that correlate with metastasis. Nat Commun 2012; 3: 1122.
31. Dong S, Hughes RC. Macrophage surface glycoproteins binding to galectin-3 (Mac-2-antigen). Glycoconj J 1997; 14: 267-74.
32. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006; 8: 1369-75.
33. Sano H. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol 2000; 165: 2156-64.
34. Sato S, Ouellet N, Pelletier I, Simard M, Rancourt A, Bergeron MG. Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J Immunol 2002; 168: 1813-22.
35. Functional Glycomics Gateway. Consortium for functional glycomics. Available from: http://www.functionalglycomics.org/; 2010. Accessed December 2012.
36. Springer GF. T and Tn, general carcinoma autoantigens. Science 1984; 224: 1198-206.
37. Hsu Y-C, Yuan S, Chen H-Y, Yu S-L, Liu C-H, Hsu P-Y, et al. A fourgene signature from NCI-60 cell line for survival prediction in non- small cell lung cancer. Clin Cancer Res 2009; 15: 7309-15.
38. Inka B. Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta 1999; 1473: 67-95.
39. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13: 58- 68.
40. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860- 7.
41. Nangia-Makker P. Galectin-3 induces endothetial cell morphogenesis and angiogenesis. Am J Pathol 2000; 156: 899-909.
42. Ueda T, Shimada E, Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin- 8 in hematogenous metastasis. J Gastroenterol 1994; 29: 423- 9.
43. Blay J-Y, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992; 52: 3317-22.
44. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6: 2702-6.
45. Burger MM. Surface changes in transformed cells detected by lectins. Fed Proc 1973; 32: 91-101.
46. Kim Y, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J 1997; 14: 569-76.
47. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci 2002; 99: 10231-3.
48. Ueda K. Glycoproteomic strategies: From discovery to clinical application of cancer carbohydrate biomarkers. Proteomics Clin Appl 2013; 7: 607- 17.
49. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009; 9: 874-85.
50. Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, et al. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci U S A 2012; 109: 261-6.
51. Yogeeswaran G, Salk PL. Metastatic potential is positively correlated with cell surface sialylation of cultured murine tumor cell lines. Science 1981; 212: 1514-6.
52. Murugaesu N, Iravani M, van Weverwijk A, Ivetic A, Johnson DA, Antonopoulos A, et al. An in vivo functional screen identifies ST6Gal- NAc2 sialyltransferase as a breast cancer metastasis suppressor. Cancer Discov 2014; 4: 304-17.
53. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: a cancer microarray database and integrated datamining platform. Neoplasia 2004; 6: 1-6.
54. The Cancer Genome Atlas [Internet]. Available from: https://tcga-data. nci.nih.gov/tcga/tcgaHome2.jsp. Accessed November 3, 2012, and January 4, 2014.